<DOC>
	<DOCNO>NCT02094300</DOCNO>
	<brief_summary>The Zenith® Dissection Clinical Trial clinical trial approve US FDA study safety effectiveness Zenith® Dissection Endovascular System treatment patient aortic dissection .</brief_summary>
	<brief_title>Zenith® Dissection Endovascular System</brief_title>
	<detailed_description />
	<criteria>Branch vessel obstruction/compromise Periaortic effusion/hematoma Resistant hypertension Persistent pain/symptoms Transaortic growth &gt; 5 mm within 3 month Transaortic diameter &gt; 40 mm . Age &lt; 18 year ; Other medical condition ( e.g. , cancer , congestive heart failure ) may cause patient noncompliant protocol , confound result , associate limited life expectancy ( i.e. , less 2 year ) Pregnant , breastfeeding , plan become pregnant within 24 month ; Unwilling unable comply followup schedule Inability refusal give inform consent Simultaneously participate another investigative device drug study . ( The patient must complete primary endpoint previous study least 30 day prior enrollment study . ) Additional medical restriction specify Clinical Investigation Plan , Additional anatomical restriction specify Clinical Investigation Plan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Aorta</keyword>
	<keyword>Thoracic</keyword>
	<keyword>Aortic dissection</keyword>
	<keyword>Rupture</keyword>
	<keyword>Type B</keyword>
	<keyword>DeBakey type III</keyword>
	<keyword>Endovascular</keyword>
</DOC>